# A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

> **NCT07011771** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Capsida Biotherapeutics, Inc.** · enrollment: 31 (estimated)

## Conditions studied

- GBA1 Parkinson Disease

## Interventions

- **DRUG:** gene therapy
- **DRUG:** gene therapy

## Key facts

- **NCT ID:** NCT07011771
- **Lead sponsor:** Capsida Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-08-18
- **Primary completion:** 2029-09
- **Final completion:** 2029-11
- **Target enrollment:** 31 (ESTIMATED)
- **Why stopped:** Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011771, "A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07011771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*